Proton pump inhibitors: misconceptions and proper prescribing practice
- 28 August 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 36 (6) , 493-500
Abstract
Purpose of review The current review summarizes and attempts to place in proper perspective the past year's literature regarding purported adverse effects of proton pump inhibitors (PPIs). Recent findings Although generally considered safe, physicians are inundated with retrospective database-driven epidemiologic studies, and meta-analyses on the same studies, claiming a panoply of serious adverse effects associated with long-term use of PPIs. The quality of the evidence underlying most of these associations is very low and cannot ascribe cause and effect. Nonetheless, these reports have stoked fears, in both prescribers and patients. As a result, patients are being harmed. Physicians are not prescribing PPIs when medically indicated and patients are stopping PPIs without consulting their caregivers. It is reassuring that a cross-sectional analysis of data from the National Ambulatory Medical Care Survey as well as a double-blinded, placebo-controlled trial report no safety concerns with PPIs, other than a possible small association with enteric infection. Most of the publicized serious putative adverse effects attributed to PPIs have been debunked in more recent and properly designed studies. Nevertheless, PPIs should be prescribed for valid indications and, when prescribed long-term, they should be used at the lowest effective dose and their ongoing need periodically assessed.Keywords
This publication has 38 references indexed in Scilit:
- Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With CirrhosisHepatology, 2019
- Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal WomenGastroenterology, 2019
- Proton pump inhibitors therapy and the risk of major osteoporotic nonhip fractures in older adults in TaiwanEuropean Journal of Gastroenterology & Hepatology, 2019
- The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancerCancer, 2019
- The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia in a National Cohort of Veteran Patients with HIVJournal of the International Association of Providers of AIDS Care (JIAPAC), 2019
- Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non–Small Cell Lung CancerTherapeutic Drug Monitoring, 2018
- The risks of long-term use of proton pump inhibitors: a critical reviewTherapeutic Advances in Drug Safety, 2018
- Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut MicrobiomeNutrition in Clinical Practice, 2018
- Maintenance proton pump inhibition therapy and risk of oesophageal cancerCancer Epidemiology, 2018
- Gastric Acid and Enteric Infections: Souring on the Use of PPIsDigestive Diseases and Sciences, 2018